Whitehawk Therapeutics, Inc. (WHWK): restructuring charge — Aadi halts PRECISION1 trial for TSC1/TSC2 cancers; cuts R&D staff 80%, extends cash runway into 2H 2026

Whitehawk Therapeutics, Inc.

PRECISION1 trial halted; IDMC found it unlikely to meet efficacy threshold for accelerated approval; 25 benefiting patients eligible for expanded access.
FYARRO Q2 2024 sales of $6.2M; company will focus on FYARRO commercial business for PEComa.
Workforce reductions: 22 employees (32% total) and 80% of R&D staff; non-recurring charges estimated $2.2-2.5M in Q3 2024.
Cash runway extended into at least 2H 2026; company hired advisory firm for comprehensive strategic review to maximize shareholder value.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Whitehawk Therapeutics, Inc. announced a restructuring with charges of approximately $2.2 to $2.5 million affecting workforce reduction (22 employees, representing approximately 32% of the Company’s workforce).

Type: restructuring
Charge: approximately $2.2 to $2.5 million
Affected area: workforce reduction
Headcount: 22 employees, representing approximately 32% of the Company’s workforce

Exact text from the filing

a workforce reduction of 22 employees, representing approximately 32% of the Company’s workforce. The Company estimates that it will incur non-recurring charges of approximately $2.2 to $2.5 million in connection with the workforce reduction, primarily consisting of severance payments, employee benefits contributions and related costs. The Company expects that

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-203889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.